PEG-MGF
Also known as: Pegylated Mechano Growth Factor, Pegylated MGF
IGF-1 analogue / Mechano Growth Factor derivative
What it is
PEG-MGF is a modified, longer-acting form of Mechano Growth Factor used by some athletes and bodybuilders for muscle repair and growth. It is categorized as a performance-enhancing research compound with very little published scientific evidence specific to this modified form. Not FDA-approved; classified as a prohibited performance-enhancing substance.
The scientific side
PEG-MGF (pegylated mechano growth factor) is classified in the reviewed literature as an IGF-1 analogue intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis. It is grouped among performance-enhancing peptides marketed as "research compounds" and encountered in online self-administration protocols. Beyond its classification as a GH-IGF-1 axis modulator, specific mechanistic details are not described in the reviewed abstract.
Class: IGF-1 analogue / Mechano Growth Factor derivative
Administration & storage
- Administration
- Injection route implied by reference to 'injection-site reactions' among reported adverse effects across this peptide class (PMID: 42395176)
- Cautions
- No regulatory approval exists for physique- or performance-related indications for PEG-MGF or related peptides.,Product composition, dose, and stacking practices in unregulated supply chains are uncertain, raising risks from unknown formulation purity.,Injection-site reactions have been reported across this class of peptides.,Biologically plausible but unproven mitogenic concerns have been noted for GH-IGF-1 axis–modulating peptides.,Sterile technique is essential for any injectable compound — universal caution.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Performance enhancement and body recomposition (putative) Animal studies only
- PEG-MGF is identified as an IGF-1 analogue marketed as a performance-enhancing 'research compound' intended to modulate the GH-IGF-1 axis. The review stratifies it into an evidence tier reflecting a complete absence of human studies, and notes that putative performance and recomposition benefits are biologically plausi PMID 42395176 Dominikowski A, et al. Frontiers in Endocrinology (2026).
Safety signals
- Endocrine and metabolic disturbances reported across GH-IGF-1 axis–modulating peptides in this class, including prolactin and cortisol elevations, appetite changes, and dysglycaemia. PMID 42395176
- Fluid retention syndromes reported across this peptide class. PMID 42395176
- Musculoskeletal symptoms (myalgia/arthralgia) reported across this peptide class. PMID 42395176
- Injection-site reactions reported across this peptide class. PMID 42395176
- Biologically plausible but unproven mitogenic concerns highlighted for GH-IGF-1 axis modulators. PMID 42395176
Protocol
200 mcg subcutaneous injection, twice per week. Cycle: 4-6 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| subcutaneous injection | 200 mcg | twice per week · 4-6 weeks | bodybuilders and strength athletes seeking muscle hypertrophy | [Community] |
| intramuscular injection | 200 mcg | twice per week · 4-6 weeks | bodybuilders targeting specific muscle groups for hypertrophy | [Community] |
| subcutaneous injection | 100 mcg | twice per week · 4-6 weeks | peptide newcomers or smaller individuals beginning PEG-MGF | [Community] |
| subcutaneous injection | 400 mcg | twice per week · 4-6 weeks | experienced bodybuilders seeking maximal hypertrophy stimulus | [Community] |
| subcutaneous injection | 200 mcg | twice per week · 4-6 weeks | athletes and biohackers using PEG-MGF alongside IGF-1 LR3 in a stacked protocol | [Community] |
| subcutaneous injection | 200 mcg | twice per week · 4-6 weeks | post-cycle (AAS) users seeking muscle retention and recovery | [Community] |
| subcutaneous injection | 200 mcg | once per week · 4-8 weeks | biohackers and older adults using PEG-MGF for anti-aging / muscle preservation | [Community] |
All studies (1)
- PMID 42395176 Animal studies only
Performance enhancement and body recomposition (putative)
Frequently asked
What is PEG-MGF and what is it used for?
PEG-MGF (pegylated mechano growth factor) is classified as an IGF-1 analogue intended to modulate the GH-IGF-1 axis. It is encountered in online self-administration communities as a purported performance-enhancing 'research compound.' However, the available peer-reviewed literature stratifies it into an evidence tier reflecting a complete absence of human clinical studies, and any performance or body recomposition benefits are described as biologically plausible but unproven.
What dose of PEG-MGF should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: No specific dosing data for PEG-MGF in humans or animals is provided in the peer-reviewed literature available for this record. The reviewed literature notes that dose information in unregulated supply chains is uncertain.
Is PEG-MGF safe to use?
The peer-reviewed literature flags several safety concerns for GH-IGF-1 axis–modulating peptides as a class, including endocrine and metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), injection-site reactions, and biologically plausible but unproven mitogenic risks. PEG-MGF has no regulatory approval for any performance- or physique-related indication, and uncertainty around product composition and purity in unregulated supply chains adds additional risk. Please consult a licensed healthcare provider.
Can I stack PEG-MGF with other peptides like IGF-1 LR3 or GHRP-6?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: The reviewed literature notes that stacking practices in unregulated supply chains carry significant uncertainty around dose and composition, and no clinical data on combination use of PEG-MGF is available in the reviewed abstracts.
Where can I buy PEG-MGF?
I don't recommend vendors or sources. Please consult a licensed provider.
Does PEG-MGF require a prescription?
The reviewed literature states there is an absence of regulatory approval for physique- or performance-related indications for peptides in this class, including PEG-MGF, and they are marketed as 'research compounds'. Specific regulatory or prescription status by jurisdiction is not addressed in the reviewed abstracts and requires manual verification with the relevant regulatory authority.
What are the side effects of PEG-MGF?
The peer-reviewed literature reports adverse effects across the class of GH-IGF-1 axis–modulating peptides, which includes PEG-MGF. These include: endocrine and metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. Biologically plausible but unproven mitogenic concerns are also highlighted. No PEG-MGF–specific adverse effect data is available in the reviewed literature.
Has PEG-MGF been studied in humans?
According to the available peer-reviewed literature, PEG-MGF is stratified into an evidence tier reflecting a complete absence of human studies. Its purported benefits are described as biologically plausible but unproven.
Can PEG-MGF help with muscle injury recovery?
I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly. The only available reviewed abstract characterises PEG-MGF as a performance-enhancing peptide with no human clinical study data supporting specific therapeutic uses.
How do I reconstitute and inject PEG-MGF?
I'm not a medical professional and can't recommend a protocol for you specifically. The reviewed peer-reviewed literature does not provide reconstitution or injection instructions specific to PEG-MGF. Injectable peptides in this class have been associated with injection-site reactions. Please consult a licensed healthcare provider before using any injectable compound.